Obesity and diabetes can affect fertility on multiple fronts: hormones, sperm production, nerves, and blood vessels
The compounds, initially approved for diabetes, can also offer significant weight loss
This microbiome shift may explain why some GLP-1 users report constipation, bloating, or altered digestion
Early evidence suggests Semaglutide's benefits extend to cardiometabolic risk reduction mechanisms independent of weight loss, potentially justifying use in leaner populations with cardiovascular disease or metabolic dysfunction
This can be particularly beneficial for individuals with insulin resistance or type 2 diabetes, even though Wegovy is specifically approved for weight management in eligible individuals
B., Persaud, C., & Jackson, A